Business Context and Reporting Period
This Form 8-K was filed by Intrexon Corporation on December 28, 2018, reporting a transaction closed on that date. The filing details the assumption of rights and obligations under a License and Collaboration Agreement originally dated March 27, 2015, involving ARES TRADING S.A. ("ARES"), Intrexon's wholly-owned subsidiary Precigen, Inc., and ZIOPHARM Oncology, Inc.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, or debt levels for the reporting period. The primary financial data disclosed relates to the transaction consideration:
- Stock Issuance: 20,640,119 shares of Intrexon common stock issued to ARES.
- Transaction Value: $150,000,000, calculated based on the volume-weighted average price of the common stock over the ten trading days prior to closing.
- Debt Instrument: A convertible note was issued and sold to ARES, convertible into Intrexon common stock or Precigen equity securities upon certain qualified financings.
Material Changes
The material change reported is the legal and financial restructuring of the Collaboration Agreement. Intrexon Corporation assumed all of ARES's rights and obligations under the agreement. This represents a shift in the contractual relationship from ARES to Intrexon regarding the collaboration with ZIOPHARM Oncology, Inc.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future performance, or specific risk factors beyond the transaction details. The transaction involves a convertible note, which introduces potential future dilution depending on the occurrence of qualified financings by Precigen. The filing references a prior Form 8-K filed on December 20, 2018, for further description of the Purchase Agreement and Convertible Note.
Investor Verification Checklist
- Verify the terms of the convertible note issued to ARES, specifically the conversion triggers and potential dilution impact.
- Review the December 20, 2018 Form 8-K for detailed terms of the Purchase Agreement and Convertible Note.
- Confirm the current status of the Collaboration Agreement with ZIOPHARM Oncology, Inc. following Intrexon's assumption of rights.
- Assess the impact of issuing 20,640,119 shares on existing shareholder equity and ownership percentages.